);
Contact

Tag: News

 

Posted on
LinkedIn Post 1
October 2025

All eyes on Fertiga in Women’s Health Week Europe 2025!

We’re thrilled to announce that Fertiga is selected to pitch at the Med Device & Therapeutics Innovation Showcase during Women’s Health Week Europe 2025 on 17 October!

Our presentation in the ‘Clinical, Diagnostic, or Treatment-based’ category will spotlight how Fertiga is redefining fertility care through science and innovation. A fantastic opportunity to connect with investors, pharma leaders, and health systems shaping the future of women’s health. 🌍💡

Posted on
LinkedIn Post 1
October 2025

Fertiga is attending BioJapan 2025 and Japan Society of Assisted Reproduction!

We’re proud to share that Elien Van Hecke, CCO at Fertiga, will be present in Yokohama at BioJapan 2025 (October 8-10) to connect with partners, discuss the future of fertility biotech, and showcase our pioneering work in IVF innovation. Looking forward to inspiring conversations and new collaborations! ✨

Nontheless, Fertiga is honored to be present at the Japan Society of Assisted Reproduction. Elien Van Hecke will engage with the reproductive medicine community and highlight our commitment to advancing fertility biotech and IVF innovation. Looking forward to meaningful exchanges and future collaborations!🌍

Posted on
LinkedIn Post 1
July 2025

Fertiga at the 41st ESHRE Annual Meeting in Paris, France

Fertiga, in collaboration with Brussels IVF and Merck KGaA, Darmstadt, Germany, has announced ground-breaking results from the AURORA-REC study on gene expression in ICSI patients treated with r-hFSH or r-hFSH & r-hLH. During AURORA-REC study we evaluated the differences in cumulus cell gene expression between two types of ovarian stimulation and proved that gene-based algorithms can predict live birth in these patient groups:

  • the accuracy achieved for women stimulated with r-hFSH was 69%
  • the accuracy achieved for women stimulated with r-hFSH & r-hLH was 88%

Posted on
LinkedIn Post 1
May 2025

All eyes on Fertiga in EMD Serono Corporate Accelerator!

We’re thrilled to share that Fertiga has been selected to pitch at Women’s Health Week (previously SiS) in New York 2025 as part of the EMD Serono Corporate Accelerator (ESCA)! It’s an honour to join a select group of innovators driving change in reproductive health, with the support of EMD Serono, Inc. and M Ventures.


Posted on
LinkedIn Post 1
August 2021

In the spotlight in VUB News!

Fertiga is a spin-off company from one of the global IVF leading centers, UZ Brussel in Belgium. UZ Brussel has been pioneering IVF, with the first ICSI baby worldwide born in 1992 from the Center of Reproductive Medicine of UZ Brussels.

Fertiga is developing the Aurora test that doubles the chances of becoming pregnant after just one fertility treatment: it improves the prediction of which egg has the highest potential for pregnancy.

“One try, one child. That should always be the goal.” – Elien Van Hecke, co-founder..

Posted on
LinkedIn Post 1
August 2021

In the spotlight in BioVox!

Fertiga, a spin-off company of the Vrije Universiteit Brussel (VUB), launched an innovation last year which considerably improve the efficiency of ICSI treatments: the Aurora test. A study with 633 patients showed that the test helped to double the pregnancy success rate of the first embryo transfer from 29 to 61 percent.

“This innovation saves people much time and emotional heartbreak,” says Elien Van Hecke, co-founder and Chief Commercial Officer (CCO) of Fertiga. “In Belgium, ICSI and IVF treatments are largely refunded by the social security system, but in countries where this is not the case the test can also save people a lot of money.”.

Posted on
LinkedIn Post 1
May 2021

In the spotlight in De Tijd!

Belgium is the world leader in research into fertility problems in couples. The start-up Fertiga is the result of this. “Helping couples who want to have children, that’s what we do it for.”

💡The core message:

  • the Brussels start-up Fertiga has developed a test that doubles the chance of success from a first IVF attempt to more than 60 percent.
  • this test costs 1,000 to 1,500 euros and is already offered at UZ Brussel.
  • the roll-out in Belgium and in the rest of the world was delayed due to the pandemic.

Posted on
LinkedIn Post 1
May 2021

We have been noticed by Foreign Affairs Belgium!

In vitro fertilization (IVF) can help women unable to naturally conceive to have a child. However, even if this expensive treatment is successful right away, it is still arduous for the couple. New technology developed by Fertiga ensures an enhanced success rate and increased comfort, while also highlighting Belgium’s position as a leader in the field of fertility research.

From a medical and health standpoint, the benefits are considerable, resulting in less physical and mental strain for the parents, saving them both time and money.

EN
EN